Metric Finance
LearnFAQ
LearnFAQ

Learn / ROIV

NASDAQ: ROIV

Roivant Sciences Ltd. (ROIV) stock, explained like you're 5

Roivant Sciences Ltd. trades on the Nasdaq under the ticker ROIV. It is a large cap company in the pharmaceutical preparations industry, part of the healthcare sector, with a market value of about 25.6 billion dollars.

Ticker
ROIV
Exchange
Nasdaq
Sector
Healthcare
Industry
Pharmaceutical Preparations
Size
Large cap, about 25.6 billion dollars

Is Roivant Sciences Ltd. a small, medium or large cap company?

Yes. Roivant Sciences Ltd. is a large cap stock. Its market cap, which is the total value of all its shares, is about 25.6 billion dollars.

Here is how you can tell. Multiply the share price by the number of shares to get the market cap, then compare it to the usual sizes. Micro cap is under 300 million dollars, small cap is 300 million to 2 billion, mid cap is 2 to 10 billion, large cap is 10 billion and up, and mega cap is over 200 billion. Market caps move every day with the share price, so treat the number as a recent snapshot.

How Roivant Sciences Ltd. makes money

  • Selling medicines, medical devices or healthcare services.
  • Insurance premiums or hospital and clinic fees.
  • Research and licensing deals.

What moves ROIV stock

  • Results from clinical trials and approvals from regulators.
  • Drug prices, insurance rules and government policy.
  • Patents running out and new competing treatments.

In the news lately

  • Roivant Sciences Ltd. (ROIV) Stock Price, News, Quote & History (Yahoo! Finance Canada)
  • Here’s How Much You Would Have Made Owning Roivant Sciences Stock In The Last 5 Years (Benzinga)
  • Roivant Sciences Ltd (ROIV) Stock Price Target & Forecast (TradingKey)
  • (ROIV) Movement Within Algorithmic Entry Frameworks (Stock Traders Daily)
  • Roivant Sciences Ltd. (ROIV) Stock Forecasts (Yahoo Finance)

Follow ROIV in your daily brief

Each trading day at 5 PM ET we post what happened to Roivant Sciences Ltd. and why it matters, in simple words. Free.

Start my free brief

Key terms to know before you follow ROIV

  • Market cap
  • P/E ratio
  • EPS (earnings per share)
  • Earnings report
  • Volatility

Questions about Roivant Sciences Ltd. stock

What does Roivant Sciences Ltd. do?

Roivant Sciences Ltd. trades on the Nasdaq under the ticker ROIV. It is a large cap company in the pharmaceutical preparations industry, part of the healthcare sector, with a market value of about 25.6 billion dollars.

What is the ticker symbol for Roivant Sciences Ltd.?

Roivant Sciences Ltd. trades under the ticker ROIV on the Nasdaq.

What is Roivant Sciences Ltd.'s market cap?

Roivant Sciences Ltd. is a large cap stock with a market cap of about 25.6 billion dollars.

How does Roivant Sciences Ltd. make money?

Selling medicines, medical devices or healthcare services. Insurance premiums or hospital and clinic fees. Research and licensing deals.

What moves ROIV stock?

Results from clinical trials and approvals from regulators. Drug prices, insurance rules and government policy. Patents running out and new competing treatments.

How can I follow ROIV stock every day?

Add ROIV to your watchlist on Metric Finance. We post a free brief every trading day at 5 PM ET that explains what happened to the stocks you follow, in simple words.

Follow ROIV daily

A free brief on Roivant Sciences Ltd. and your other stocks, every trading day at 5 PM ET.

Start my free brief

Similar stocks

  • NVS · Novartis AG
  • AZN · Astrazeneca PLC
  • NVO · Novo Nordisk A S
  • VRTX · Vertex Pharmaceuticals Inc / Ma

Similar stocks

  • NVSNovartis AG
  • AZNAstrazeneca PLC
  • NVONovo Nordisk A S
  • VRTXVertex Pharmaceuticals Inc / Ma

Compare ROIV: ROIV vs NVS, ROIV vs AZN, ROIV vs NVO

Educational information, not financial advice. This guide explains the business in general terms and does not include live prices.

Metric Finance

Stocks explained like you're 5.

Product

  • Learn
  • FAQ
  • Your account

Legal

  • Privacy
  • Terms

Support

  • Contact
  • Unsubscribe

© 2026 Metric Finance

Built by Yashna & Vansh · Not investment advice · Market data may be delayed